

## UMC, Inc.

1770 Park Street, Suite 105, Naperville, IL 60563

---

630-229-6338

www.umcinc.com

info@umcinc.com

# Annual Report

For the period ending December 31, 2025 (the "Reporting Period")

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was:

663,866,911 as of December 31, 2025 (Current Reporting Period Date or More Recent Date)

663,866,911 as of December 31, 2025 (Most Recent Completed Fiscal Year End)

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

### **Change in Control**

Indicate by check mark whether a Change in Control<sup>4</sup> of the company has occurred during this reporting period:

Yes:  No:

---

<sup>4</sup> "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

United Medicorp Texas, Inc. was incorporated in the State of Texas on March 13, 1989 ("UMC-Texas"). On July 10, 1989, in an exchange of stock, UMC-Texas was acquired by Gamma Resources, Inc., a publicly-owned Delaware shell corporation, which simultaneously changed its name to United Medicorp, Inc. On May 24, 2007, the Company filed "Articles of Amendment to the Articles of Incorporation of United Medicorp, Inc. whereby United Medicorp, Inc. was renamed UMC, Inc. (the "Company" or "UMC").

The Company has three wholly-owned subsidiaries. United MediCorp LLC ("UMCL"), formed July 30, 2016, and United MediCorp Acquisitions LLC ("UMCA"), formed July 22, 2020 (collectively, "SUBS"). On May 5, 2025, the Company formed UMCA SPV1 LLC, a limited liability company in the State of Illinois. UMCA SPV1 LLC is a single-member Special Purpose Entity (United MediCorp Acquisitions LLC being the sole Member).

Through its SUBS, the Company is engaged in the purchase, management, and collection of charged-off accounts receivable.

Current State and Date of Incorporation or Registration: Delaware  
Standing in this jurisdiction: (e.g., active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:  
N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

1770 Park Street, Suite 105, Naperville, IL 60563

Address of the issuer's principal place of business:

*Check if principal executive office and principal place of business are the same address:*

\_\_\_\_\_

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:  Yes:  If Yes, provide additional details below:

\_\_\_\_\_

**2) Security Information**

**Transfer Agent**

Name: Equiniti Trust Company LLC

Phone: 718-921-8300

Email: cleibell@astfinancial.com

Address: 6201 15<sup>th</sup> Avenue, Brooklyn, NY 11219

**Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	<u>UMCN</u>	
Exact title and class of securities outstanding:	<u>Common Stock</u>	
CUSIP:	<u>902846104</u>	
Par or stated value:	<u>\$0.01</u>	
Total shares authorized:	<u>750,000,000</u>	as of date: <u>December 31, 2025</u>
Total shares outstanding:	<u>663,866,911</u>	as of date: <u>December 31, 2025</u>
Total number of shareholders of record:	<u>177</u>	as of date: <u>December 31, 2025</u>

*Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.*

\_\_\_\_\_

**Other classes of authorized or outstanding equity securities that do not have a trading symbol:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of the security:	<u>Preferred Stock</u>	
Par or stated value:	<u>\$0.01</u>	
Total shares authorized:	<u>250,000,000</u>	as of date: <u>December 31, 2025</u>
Total shares outstanding:	<u>0</u>	as of date: <u>December 31, 2025</u>
Total number of shareholders of record:	<u>0</u>	as of date: <u>December 31, 2025</u>

*Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.*

\_\_\_\_\_

**Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

1. **For common equity, describe any dividend, voting and preemption rights.**

Common stock – one vote per share, no other rights or privileges.

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

No designations have been completed for the authorized preferred stock. Votes, rights, or privileges of preferred shares will be determined before issuance.

3. **Describe any other material rights of common or preferred stockholders.**

N/A

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

N/A

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No:  Yes:  (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance</u> :			*Right-click the rows below and select "Insert" to add rows as needed.						
Date <u>December 31, 2023</u> Common: 642,232,383 Preferred: <u>-0-</u>									
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to.  ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
3/29/2024	New Issuance	11,565,217	Common	\$0.0115	No	Stevens Financial Group, LLC - Dannel Stevens	Conversion of debt	Restricted	Rule 144
3/29/2024	New Issuance	1,478,261	Common	\$0.0115	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144
12/31/2024	New Issuance	1,068,032	Common	\$0.04	No	Stevens Financial Group, LLC - Dannel Stevens	Conversion of debt	Restricted	Rule 144
12/31/2024	New Issuance	189,353	Common	\$0.04	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144
3/31/2025	New Issuance	2,260,513	Common	\$0.04	No	Stevens Financial Group, LLC - Dannel Stevens	Conversion of debt	Restricted	Rule 144
6/30/2025	New Issuance	254,581	Common	\$0.04	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144

6/30/2025	New Issuance	188,196	Common	\$0.04	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144
6/30/2025	New Issuance	865,256	Common	\$0.04	No	Stevens Financial Group, LLC - Danniell Stevens	Conversion of debt	Restricted	Rule 144
9/30/2025	New Issuance	251,979	Common	\$0.04	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144
9/30/2025	New Issuance	1,589,459	Common	\$0.04	No	Stevens Financial Group, LLC - Danniell Stevens	Conversion of debt	Restricted	Rule 144
12/31/2025	New Issuance	1,923,681	Common	\$0.04	No	Stevens Financial Group, LLC - Danniell Stevens	Conversion of debt	Restricted	Rule 144
Shares Outstanding on Date of This Report:									
Ending Balance:									
Date <u>December 31, 2025</u>									
Common: <u>663,866,911</u>									
Preferred: <u>-0-</u>									

**Example:** A company with a fiscal year end of December 31<sup>st</sup> 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

\_\_\_\_\_

## B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion <sup>5</sup>	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
1/7/2025	\$100,000	\$0	06/30/25	\$0.04 per share	2,515,097		Stevens Financial Group, LLC - (Danniell Stevens), and Cleston R. Lord, Jr.	Loan

<sup>5</sup> The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

5/1/25	\$50,000	\$0	06/30/25	\$0.04 per share	1,053,452		Stevens Financial Group, LLC (Danniel Stevens), and Cleston R. Lord, Jr.	Loan
5/1/25	\$50,000	\$0	09/30/25	\$0.04 per share	1,841,438		Stevens Financial Group, LLC (Danniel Stevens), and Cleston R. Lord, Jr.	Loan
8/26/25	\$75,000	\$0	12/31/25	\$0.04 per share	1,923,681		Stevens Financial Group, LLC (Danniel Stevens), and Cleston R. Lord, Jr.	Loan
1/09/26	\$175,000	\$175,879	03/31/26	\$0.04 per share	4,396,973		Stevens Financial Group, LLC (Danniel Stevens), and Cleston R. Lord, Jr.	Loan
<b>Total Outstanding Balance:</b>		\$175,879	<b>Total Shares:</b>		11,730,641			

Any additional material details, including footnotes to the table are below:

\_\_\_\_\_

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on [www.OTCMarkets.com](http://www.OTCMarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company provides accounts receivable management and "after collection" solutions to healthcare providers. The Company engages proprietary workflows and licensed software to provide these services to its customers, primarily independent healthcare providers. In addition, the Company also offers traditional collection services through its partners.

Management believes it has developed a line of services that address healthcare providers' collection and cash-flow needs. The Company has partnered with other companies that provide enhanced software, computer hardware, maintenance, and other valuable services specifically designed for healthcare providers. Management believes these efforts will produce a system that enhances cash flow for the Company's customers.

The Company offers two primary services: Bad Debt Collection Services and a Debt Purchasing Program.

**Bad Debt Collection Services:** This service involves third-party collection of accounts written off as bad debt.

**Debt Purchasing Program:** Healthcare providers participating in the Debt Purchasing Program agree to transfer ownership of accounts, or a portfolio of accounts, to the Company for an agreed-upon price significantly less than the face amount of the account (s) or portfolio. UMC and its affiliates assume all risks and receive all collections from such purchases.

During 2024, under its debt purchasing program, the Company entered into three contracts to acquire four account portfolios. During the year ending December 31, 2024, United MediCorp Acquisitions LLC generated \$3,961 in revenue from collections. During 2025, the Company acquired two (2) additional portfolios. During the year ending December 31, 2025, United MediCorp Acquisitions LLC generated \$28,550 in revenue from collections. The Company has not begun generating revenue from its other potential revenue streams.

B. Please list any subsidiaries, parents, or affiliated companies.

United MediCorp LLC, United MediCorp Acquisitions LLC, and UMCA SPV1 LLC

C. Describe the issuers' principal products or services.

The Company offers two primary services: Bad Debt Collection Services and its Debt Purchasing Program.

## 5) Issuer's Facilities

*The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.*

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company's corporate office is located in 1,500 square feet of leased office space in Naperville, Illinois. This space is provided rent-free from a related party. Management believes that the facilities are well located and in good condition. The Company's future facility requirements will depend on the success of its business, and management believes there is adequate office space available should its space requirements increase.

## 6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Stevens Financial Group, Danniell Stevens	Chairman & CEO	Aurora, Illinois	572,764,006	Common	86.3%
Cleston R. Lord, Jr.	Corporate Secretary	Bronx, New York	8,762,370	Common	1.3%
Benjamin Willingham	Investor	Naperville, Illinois	45,830,000	Common	6.9%
Karen White	Chief Operating Officer, United MediCorp Acquisitions LLC	Bellbrook, Ohio	0	Common	N/A

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, log in to [www.OTCIQ.com](http://www.OTCIQ.com) to update your company profile.

## 7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

## 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, update your company profile.

Securities Counsel



Name: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

Accountant or Auditor

Name: Cicely A Parada-Obreque, CPA  
Firm: Integrität Audit Accounting & Advisory, LLC  
Address 1: 1825 NW Corporate Blvd., Suite 110  
Address 2: Boca Raton, FL 33431  
Phone: (561) 210-7284  
Email: cicely@integritatcpa.com

Investor Relations

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

*All other means of Investor Communication:*

X (Twitter): \_\_\_\_\_  
Discord: \_\_\_\_\_  
LinkedIn: \_\_\_\_\_  
Facebook: \_\_\_\_\_  
[Other ] \_\_\_\_\_

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement.** This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Vanessa J. Schoenthaler, Partner  
Firm: Saul Ewing LLP  
Nature of Services: Securities Attorneys  
Address 1: 1270 Avenue of the Americas, Ste. 2800  
Address 2: New York, New York 10020  
Phone: (212) 980-7208  
Email: vanessa.schoenthaler@saul.com

Name: Ann Leong, CPA  
Firm: KCL Accounting Services, LLC  
Nature of Services: Accounting & Bookkeeping services  
Address 1: 1255 S. State Street  
Address 2: Chicago, IL 60605  
Phone: (312) 437-0645  
Email: annleo38@yahoo.com

**9) Disclosure & Financial Information**

A. This Disclosure Statement was prepared by (name of individual):

Name: Rachel Boulds  
Title: Outsourced CPA  
Relationship to Issuer: Service Provider

B. The following financial statements were prepared in accordance with:

- IFRS  
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Rachel Boulds  
Title: Outsourced CPA  
Relationship to Issuer: Service Provider

Describe the qualifications of the person or persons who prepared the financial statements:<sup>6</sup> Licensed CPA in the State of Utah.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

**Financial Statement Requirements:**

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

**10) Issuer Certification**

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Danniel Stevens certify that:

1. I have reviewed this Disclosure Statement for UMC, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

---

<sup>6</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

April 2, 2026

/s/ Danniell Stevens

*Principal Financial Officer:*

I, Danniell Stevens certify that:

1. I have reviewed this Disclosure Statement for UMC, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

April 2, 2026

/s/ Danniell Stevens

**UMC, INC.**  
**CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED**  
**DECEMBER 31, 2025**

**UMC, INC. AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**

	December 31, 2025	December 31, 2024
<u>ASSETS</u>		
Current Assets:		
Cash and cash equivalents	\$ 2,136	\$ 17,348
Receivables from collection agency	167	801
Prepaid expense	156	780
Total current assets	<u>2,459</u>	<u>18,929</u>
Non Current Assets:		
Collection receivable - collection portfolios, net	138,483	20,746
Total non current assets	<u>138,483</u>	<u>20,746</u>
Total assets	<u>\$ 140,942</u>	<u>\$ 39,675</u>
<u>LIABILITIES AND STOCKHOLDERS' EQUITY</u> <u>(DEFICIT)</u>		
Current Liabilities:		
Accounts payable and accrued liabilities	\$ 61,769	\$ 20,207
Total current liabilities	<u>61,769</u>	<u>20,207</u>
Total liabilities	<u>61,769</u>	<u>20,207</u>
Stockholders' equity (deficit):		
Preferred stock, \$0.01 par value; 250,000,000 shares authorized; no shares issued and outstanding,	—	—
Common stock, \$0.01 par value; 750,000,000 and 200,000,000 shares authorized, respectively; 663,866,911 and 656,533,246, shares issued and outstanding, respectively	6,638,669	6,565,332
Additional paid in capital	19,386,761	19,143,495
JV capital	81,293	—
Accumulated deficit	(26,027,550)	(25,689,359)
Total stockholders' equity	<u>79,173</u>	<u>19,468</u>
Total liabilities and stockholders' equity	<u>\$ 140,942</u>	<u>\$ 39,675</u>

*The accompanying notes are an integral part of these consolidated financial statements.*

**UMC, INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**

	For the Years Ended December 31,	
	2025	2024
Revenues	\$ 28,550	\$ 3,961
Cost of revenue		
Collection costs	10,719	—
Total cost of revenue	10,719	—
Gross margin	17,831	3,961
Operating Expenses:		
General and administrative	349,793	179,822
Total operating expenses	349,793	179,822
Loss from operations	(331,962)	(175,861)
Other Expenses:		
Interest expense	(3,225)	(352)
Other income	—	176
Write off of collection receivable	(3,004)	—
Total other expenses	(6,229)	(176)
Net Loss	\$ (338,191)	\$ (176,037)
Net loss per share	\$ (0.00)	\$ (0.00)
Weighted average shares outstanding, basic and diluted	659,359,907	652,131,132

*The accompanying notes are an integral part of these consolidated financial statements.*

**UMC, INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)**  
**FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024**

	Common Stock		Additional Paid in Capital	JV Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	Shares	Amount				
Balance, December 31, 2023	642,232,383	\$ 6,422,324	\$ 19,062,952	\$ —	\$ (25,513,322)	\$ (28,046)
Common stock issued for conversion of debt – related party	14,300,863	143,008	57,287	—	—	200,295
Contributed rent – related party	—	—	23,256	—	—	23,256
Net loss	—	—	—	—	(176,037)	(176,037)
Balance, December 31, 2024	656,533,246	6,565,332	19,143,495	—	(25,689,359)	19,468
Contributed rent – related party	—	—	23,256	—	—	23,256
Common stock issued for conversion of debt – related party	7,333,665	73,337	220,010	—	—	293,347
Joint investment capital contribution	—	—	—	81,293	—	81,293
Net loss	—	—	—	—	(338,191)	(338,191)
Balance, December 31, 2025	663,866,911	6,638,669	\$ 19,386,761	\$ 81,293	\$ (26,027,550)	\$ 79,173

*The accompanying notes are an integral part of these consolidated financial statements.*

**UMC, INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**

	For the Years Ended December 31,	
	2025	2024
<b>Cash flows from operating activities:</b>		
Net loss	\$ (338,191)	\$ (176,037)
Adjustments to reconcile net loss to net cash used by operating activities:		
Owner's contributed lease expense	23,256	23,256
Amortization of allowance for credit losses	(30,426)	(3,960)
Collection costs settled from receivable balance	10,719	431
Write off collection receivable	3,004	—
Changes in assets and liabilities:		
Prepaid and deposits	624	4,332
Accounts payable and accrued liabilities	41,563	7,174
Due to related party	—	—
Receivables from collection agency	634	—
Accrued interest	1,449	295
<b>Net cash used by operating activities</b>	<b>(287,368)</b>	<b>(144,509)</b>
<b>Cash flows from investing activities:</b>		
Purchase of collection portfolios	(119,927)	(20,987)
Proceeds from collection receivables	18,893	2,969
<b>Net cash used in investing activities</b>	<b>(101,034)</b>	<b>(18,018)</b>
<b>Cash flows from financing activities:</b>		
Proceeds received from convertible notes payable - related party	291,897	167,900
JV investment	81,293	—
<b>Net cash provided by financing activities</b>	<b>373,190</b>	<b>167,900</b>
<b>Net change in cash</b>	<b>(15,212)</b>	<b>5,373</b>
Cash at beginning year	17,348	11,975
<b>Cash at end of year</b>	<b>\$ 2,136</b>	<b>\$ 17,348</b>
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid for interest	\$ —	\$ 389
Cash paid for taxes	\$ —	\$ —
<b>Supplemental disclosure of non-cash activity:</b>		
Common stock issued for conversion of amounts due to related parties	\$ 293,347	\$ 200,295

*The accompanying notes are an integral part of these consolidated financial statements.*



**UMC, INC. AND SUBSIDIARIES**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**DECEMBER 31, 2025**  
**(Unaudited)**

**NOTE 1 — NATURE OF OPERATIONS**

United Medicorp Texas, Inc. was incorporated in the State of Texas on March 13, 1989 ("UMC-Texas"). On July 10, 1989, in an exchange of stock, UMC-Texas was acquired by Gamma Resources, Inc., a publicly-owned Delaware shell corporation, which simultaneously changed its name to United Medicorp, Inc. On May 24, 2007, the Company filed "Articles of Amendment to the Articles of Incorporation of United Medicorp, Inc., whereby United Medicorp, Inc. was renamed UMC, Inc. (the "Company", or "UMC").

The Company has three wholly-owned subsidiaries. United MediCorp LLC ("UMCL") was formed on July 30, 2016, and United MediCorp Acquisitions LLC ("UMCA") was formed on July 22, 2020 and on May 5, 2025, the Company formed UMCA SPV1 LLC, a limited liability company in the State of Illinois (collectively, "SUBS"). UMCA SPV1 LLC ("SPV1") is a single-member Special Purpose Entity and a variable interest entity ("VIE"), (United MediCorp Acquisitions LLC being the sole member).

Through its SUBS, the Company is engaged in the purchase, management, and collection of charged-off accounts receivable. The Company's fiscal year-end is December 31st.

**NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Basis of Presentation*

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") as found in the Accounting Standards Codification ("ASC") and the Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB") and are expressed in US Dollars. Significant accounting policies applicable to the Company are summarized as follows:

*Use of Estimates*

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates consist of allowance for credit losses and the estimated value of lease capital contributions.

*Principles of Consolidation*

The accompanying consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, and VIE, UMCL, UMCA, and SPV1. All significant intercompany transactions and balances have been eliminated in consolidation.

*Cash and Cash Equivalents*

The Company considers all highly liquid investments with an original maturity date of three months or less at the time of purchase to be cash equivalents. The Company has cash of \$2,136 and \$17,348 as of December 31, 2025, and 2024, respectively.

*Allowance for Credit Losses*

The Company estimates its allowance for credit losses using the Current Expected Credit Loss (CECL) model under ASC 326. The CECL model requires recognition of expected credit losses over the contractual life of financial assets as of the reporting date, taking into account the nature of the debt, industry expectations, current conditions, and reasonable and supportable forecasts.

Financial assets subject to CECL include trade receivables. The Company groups its financial assets based on shared risk characteristics and evaluates them collectively. The allowance is measured using a combination of historical activity, industry expectations, adjusted for current economic trends, and forward-looking factors such as industry outlook and macroeconomic indicators (e.g., unemployment rate, GDP).

Under CECL, the carrying amount of a financial asset (net of the allowance for credit losses) represents the amount the Company expects to collect. This means that when the CECL estimate is appropriately recorded, the net reported balance of financial assets reflects management's best estimate of collectible cash flows, based on available and supportable information.

Management reviews the adequacy of the allowance at each reporting period and updates estimates as appropriate. Changes in estimates are recorded in the income statement as a component of credit loss expense.

#### Related Party Transactions

Under ASC 850 "Related Party Transactions," an entity or person is considered to be a "related party" if it has control, significant influence, or is a key member of management personnel or affiliate. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. The Company, in accordance with ASC 850 presents disclosures about related party transactions and outstanding balances with related parties. In accordance with SAB Topic 5.T, "Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)", if a principal stockholder settles an obligation on behalf of the entity, it should be reflected as an expense in the company's financial statements with a corresponding credit to contributed (paid-in) capital, unless the stockholder's action is caused by a relationship or obligation completely unrelated to their position as a stockholder or such action clearly does not benefit the company. Related parties advance funds to sustain operations, and a related party provides premises for the Company's operations. The market value of premises provided is material and represents an obligation or expense that benefits the Company; therefore, the Company is required to incur this expense at its market value.

#### Fair Value of Financial Instruments

The fair value is the exit price that would be received upon the sale of an asset, or the amount required to transfer a liability, in an orderly transaction between market participants. As such, the fair value of a financial instrument is a market-based measurement determined using the assumptions market participants would use to price an asset or liability.

A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:

- Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2: Observable inputs that reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3: Unobservable inputs reflecting our own assumptions incorporated in valuation techniques used to determine fair value. These assumptions must be consistent with market participants' assumptions that are reasonably available.

On December 31, 2025, there are no instruments requiring fair value hierarchy disclosure. The carrying amount of the Company's financial assets and liabilities, such as cash, prepaid expenses, accounts payable, and accrued expenses approximate their fair value because of the short maturity of those instruments.

#### Derivative Liabilities – Conversion Features

The Company evaluates whether embedded conversion features in its financial instruments meet the criteria for separate accounting under ASC 815, "Derivatives and Hedging." If the conversion feature is not clearly and closely related to the host debt instrument and does not meet the scope exception for equity classification, it is bifurcated and accounted for as a derivative liability.

Derivative liabilities are initially measured at fair value on the issuance date and remeasured at each reporting period, with changes in fair value recognized in earnings. The fair value of these liabilities is determined using appropriate valuation models, such as the Black-

Scholes or binomial option pricing models, incorporating inputs including the Company's stock price, volatility, risk-free interest rate, and the terms of the conversion feature. There was no convertible debt outstanding on December 31, 2025, and 2024, and therefore no derivative considerations were required or value determined.

### Joint Venture Investment

The Company participates in joint investment arrangements under which third-party investors contribute capital to fund the acquisition of investment portfolios. The related investor interests are evaluated under applicable U.S. GAAP, including ASC 480, to determine whether such amounts should be classified as equity or as liabilities. To the extent investor capital is not subject to an unconditional obligation of repayment and returns are dependent upon the performance and cash flows of the underlying portfolio, such amounts are presented within stockholders' equity as JV capital.

Amounts distributable to JV investors, including return of capital and contractual profit-based returns, are not recognized as liabilities until the related proceeds have been realized and the Company has a present obligation to remit such amounts under the applicable agreement. Once that obligation arises, the Company recognizes a liability for the amount due to the JV investor, with a corresponding reduction to stockholders' equity. Such amounts are presented in the consolidated balance sheets as distributions payable or due to JV investors.

### Leases

The Company has a month-to-month lease arrangement exempt from ASC 842 lease recognition because it is short-term. The lease is for 1,500 square feet of office space at a reasonable market value, from the principal stockholder, for no consideration. In accordance with SAB Topic 5.T, if a principal stockholder settles an obligation on behalf of the Company, which benefits the Company, it should be reflected as an expense in the Company's financial statements with a corresponding credit to contributed (paid-in) capital, at its market value. Management considers this arrangement a short-term obligation to provide office space, satisfied by the stockholder on a month-to-month basis; it therefore records the lease value as an expense, records a capital contribution, and is exempt from recognizing the lease under ASC 842. There is currently no long-term intention to maintain this lease due to the business's growth projections; within a year or less, the premises may not suit the Company's needs.

### Equity

In accordance with ASC 505 "Equity," the Company considers an equity instrument to be any contract that evidences a residual interest in the assets of an entity after deducting all its liabilities. The Company's common shares are classified as equity instruments. Incremental costs directly attributable to the issuance of new shares are recognized in equity as a reduction of the gross proceeds received from the issuance of the shares. Share capital is reported on the balance sheet and statement of changes in shareholders' deficit.

### Basic and Diluted Loss Per Share

Under ASC 260 "Earnings Per Share," the Company presents basic and diluted earnings (loss) per share ("EPS") amounts on the face of the statements of operations. Basic EPS is computed by dividing income (loss) available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued and acquired during the period are weighted by the portion of the period during which they were outstanding. The computation of diluted EPS is similar to that of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. There were no potentially dilutive securities outstanding at December 31, 2025, and 2024. Additionally, diluted amounts are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share.

### Revenue Recognition

The Company recognizes revenue under ASC 606, "Revenue from Contracts with Customers," and in accordance with ASC 326, "Financial Instruments-Credit Losses". The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:

Step 1: Identify the contract with the customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when the Company satisfies a performance obligation.

The contract with the customer is determined to be the acquisition agreement with the Seller to pursue the collection of patient balances for the fee of whatever amount is collected.

The performance obligation is the service of pursuing collections of the Seller's patient balances.

The transaction price (sales price the Company is entitled to receive for services) is a range and is determinable upon collections realized. The potential maximum collections would be the present value of the account balance acquired, as demonstrated in the actual account balance list obtained from the Seller, and the Buyer's estimated minimum collections would be the consideration paid for the account. The agreement does not guarantee any collections.

There is a single performance obligation, and therefore, the allocation to performance obligations would not apply to the nature of revenue.

In consideration that the agreement does not guarantee any collections, revenue would only be recognized after the cost for the account is recuperated, and collections exceed the cost the buyer paid for the account.

When determining the transaction price, the Company also considers the effects of all the following:

- Variable consideration.
- Constraining estimates of variable consideration.
- The existence of a significant financing component in the contract.
- Noncash consideration.
- Consideration payable to a customer.

There is no determinable variable consideration, significant financing component, non-cash consideration, or consideration payable to customers.

#### Collection Services to Independent Healthcare Providers

The Company generates revenues from collection services for balances owing to independent healthcare providers. UMCA acquires patient healthcare balances with deteriorated credit quality. The accounts acquired by UMCA consist of unpaid service balances and do not include any previously assessed interest or fees. The accounts are sold and transferred to UMCA without recourse and representation or warranties of any kind. UMCA assumes all risks of collections. The seller agrees to sell, convey, transfer, and assign to UMCA customer accounts for a fee. The contracts purchased in 2024 and 2025 indicate a fee or purchase consideration with ranges from 0.35% to 4.25% of the balance owed by customers, a significant discount to the face amount. These accounts are trade receivables, financial assets with no effective interest rates, discounts, or premiums. The seller may recall any account after the acquisition date that it or a prior holder of the account determines may be subject to litigation, threatened litigation, adversarial administration, or that it otherwise determines is in its interest to recall to preserve or defend its rights or interests. If such notice is delivered to UMCA, UMCA would immediately cease all communications with accountholders and collection activities, have its tradeline removed from any credit reporting agencies, and update the tradeline status to "Recalled by Seller". If there is any regulatory adjustment to a balance owed, the seller of these accounts will update UMCA to adjust accordingly. Within five (5) business days of UMCA obtaining notice from the seller of an account recall or an agreed repurchase of account(s) by the seller, UMCA will transfer all necessary records and rights back to the seller, and the seller is to pay the repurchase price. From the start of account acquisitions in 2024 to December 31, 2025, there has been no such recall.

In accordance with ASC 326, the acquired customer accounts are determined to be Purchased Financial Assets with Credit Deterioration (PCD). ASC requires special accounting for the acquisition of debt with deteriorated credit quality. At initial recognition, the debt instrument is booked at its present value as "Collections Receivable." Any debt discount or premium is recorded, the cash paid to acquire the instrument is credited, and the remaining present value is allocated to "Allowance for Credit Losses." At subsequent measurement,

the principal would be reduced when payments are received for each related debt. Collections more than the consideration paid for each customer's account would result in the amortization of "Allowance for Credit Losses" and the recognition of "Collection Revenues."

Additionally, the Company engages third-party debt collection agencies to recover outstanding balances on its behalf, pursuant to an agreed-upon fee structure. The agencies report to the Company collections by the 5th day of the subsequent month. In accordance with ASC 310 - Receivables and ASC 326 - Financial Instruments - Credit Losses, at each period end the full collections received by the agency is applied against the collections receivable reducing its balance, the amount retained by the agency for their services is incurred as a cost of services, accounts receivable is increased for the net amount the agency is to remit to the Company. Similarly, as with collections made directly, the portion of total collections by agencies that exceed the cost paid for the account is amortized from "Allowance for Credit Losses" and recognized as revenue.

### Operating Segments

Operating segments are defined as components of an entity for which discrete financial information is available and regularly reviewed by the Chief Operating Decision Maker ("CODM") or decision-maker group in deciding how to allocate resources to an individual segment and in assessing performance. Our chief operating decision-making group is composed of the Chief Executive Officer. The Company has one operating segment generating revenue as of December 31, 2025, and 2024.

### Recently Issued Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the disclosure requirements for income taxes, including additional disaggregation of rate reconciliation and income taxes paid. The standard is effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 in the annual financial statements for the year ended December 31, 2024, and for interim periods beginning in 2025. The adoption had no impact on the Company's financial statements.

In October 2024, the FASB issued ASU 2024-04, Debt—Modifications and Extinguishments (Subtopic 470-50): Induced Conversions of Convertible Debt Instruments, which clarifies the accounting for induced conversions of convertible debt. The standard is effective for annual periods beginning after December 15, 2025. The Company adopted ASU 2024-04 in the annual financial statements for the year ended December 31, 2025, and for interim periods beginning in 2026. The adoption had no impact on the Company's financial statements.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily disclosure of significant segment expense categories and amounts for each reportable segment. The new standard is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 in the annual financial statements for the year ended December 31, 2024, and for interim periods beginning in 2025. The adoption had no impact on the Company's financial statements.

The Company periodically reviews newly issued accounting standards. Although some of these accounting standards may apply to the Company, it has not identified any new standards that it believes merit further discussion or changes to its adopted policies, and it expects that none will have a significant impact on its financial statements.

### Income Taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences of differences between the carrying amounts in the financial statements and their respective income tax basis (temporary differences). The effect of a change in tax rates on deferred income tax assets and liabilities is recognized in income in the period that includes the enactment date.

FASB Accounting Standards Codification Topic 740, Income Taxes ("ASC 740"), clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not-recognition threshold to be recognized. ASC 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in

interim periods, disclosure, and transition. We have determined that the Company does not have uncertain tax positions on its tax returns for the years 2025 and prior. Based on the evaluation of the 2025 transactions and events, the Company does not believe it has any material uncertain tax positions that require measurement.

The IRS requires all domestic corporations in existence for any part of the tax year to file an income tax return, whether or not they have taxable income. The Company incurred a loss for the fiscal years ended December 31, 2024, and 2023, and has filed tax returns for both years. The Company has not received any notifications from the IRS. Reported tax benefits and valuation allowances are the Company's best estimate of its tax positions and have not been reviewed by the taxing authority.

The Company's policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets at December 31, 2025, and 2024, and has not recognized interest and/or penalties in the consolidated statement of operations for the years ended December 31, 2025, and 2024.

The Company is subject to taxation in the United States and the State of Delaware. The Company's federal and applicable state income tax returns for the past three years remain subject to examination by the respective tax authorities.

### **NOTE 3 — GOING CONCERN**

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. On a consolidated basis, the Company has incurred significant operating losses since its inception. For the years ended December 31, 2025, and 2024, the Company incurred net losses of \$338,191 and \$176,037, respectively. On December 31, 2025, and 2024, the Company had an accumulated deficit of \$26,027,550 and \$25,689,358, negative working capital of \$59,310 and \$1,277, and cash balances of \$2,136 and \$17,348, respectively.

The Company does not expect that existing operational cash flows will be sufficient to fund anticipated operations, which raises substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the issuance date of this report. Therefore, the Company will need to raise additional funds and is currently exploring alternative financing sources. Historically, the Company has raised capital through notes and convertible loans from a related party as an interim measure to finance working capital and will continue to do so. The Company plans to raise additional capital through the sale of common stock or other securities, as well as short-term loans.

The ability to recognize revenue and cash receipts is contingent upon, but not limited to, the acceptable performance of the services delivered. If the Company cannot raise additional capital and/or close on some of its revenue-producing opportunities in the near term, the carrying value of its assets may be materially impacted. The consolidated financial statements do not include any adjustments related to the recovery and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.

Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from its directors. Management is also working to secure new financing. The Company's ability to obtain the new funding is not known at this time.

### **NOTE 4 — CONCENTRATION AND CREDIT RISK**

Financial instruments that potentially subject the Company to credit risk consist principally of cash and collection receivables. Cash is maintained with a creditworthy major financial institution in the USA. The Company maintains cash in a bank account insured by the Federal Deposit Insurance Corporation ("FDIC") up to \$250,000. As of December 31, 2025, and 2024, no cash balances were held in excess of federally insured limits. The risk of non-collection of the collection receivable is uniquely high due to the nature of charged-off patient accounts acquired; these balances are reported net of a significant allowance for potential non-collection, see Note 6.

Currently, the Company's primary sources of capital to sustain operations come from its CEO (principal shareholder), a related entity controlled by the CEO, and the Company's Corporate Secretary.

On December 31, 2025, amounts owed to two vendors represented 26.7% and 23.0% of total accounts payable, respectively, aggregating to 49.7% of total accounts payable.

On December 31, 2024, the amounts owed to three vendors were 60.2%, 10% and 11.4%, respectively, and represented 81.6% of total accounts payable and accrued liabilities.

#### NOTE 5 — PREPAID EXPENSES

On December 31, 2025, the Company had \$156 in prepaid insurance expense for its 2026 coverage. On December 31, 2024, the Company had \$780 in prepaid insurance expense for its 2025 coverage.

#### NOTE 6 — COLLECTION RECEIVABLES

On January 4, 2024, UMCA entered into an accounts receivable purchase agreement with an unrelated party to purchase charged-off patient accounts for \$12,643.

On January 15, 2024, UMCA entered into an accounts receivable purchase agreement with an unrelated party to purchase charged-off patient accounts for \$2,740.

On March 5, 2024, UMCA entered into an accounts receivable purchase agreement with an unrelated party to purchase charged-off patient accounts for \$5,604.

On January 23, 2025, UMCA entered into a sales and purchase agreement with an unrelated party to purchase charged-off patient accounts for \$26,164.

On December 26, 2025, UMCA SPV1 and its funding partner purchased a portfolio of accounts for \$93,763 plus an additional brokerage cost of \$1,875.

As of December 31, 2025, total Collections Receivable amounted to \$29,278,131, with an Allowance for Credit Losses of \$29,139,648, resulting in a net realizable value of \$138,483. As of December 31, 2024, total Collections Receivable amounted to \$489,601, with an Allowance for Credit Losses of \$468,855, resulting in a net realizable value of \$20,746. The Company evaluates account holders' responsiveness in each reporting period to determine whether adjustments to the Allowance for Credit Losses are necessary. For the year ended December 31, 2025, the Company collected \$29,612 in gross amounts, of which \$28,550 was revenue earned. Collection receivable activity is as follows:

Description	December 31, 2025	December 31, 2024
Collection receivable beginning balance	\$ 489,601	\$ —
Collection accounts purchased	28,874,914	493,802
Collections	(18,726)	(2,969)
Receivables from collection agency	(167)	(801)
Collection costs for agency	(10,719)	(431)
Accounts written off	(56,772)	—
Collection Receivable ending balance	\$ 29,278,131	\$ 489,601
Allowance for doubtful accounts	(29,139,648)	(468,855)
Collection Receivable, net	\$ 138,483	\$ 20,746

#### NOTE 7 — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities were comprised of the following:

	December 31, 2025	December 31, 2024
Trade accounts payable	\$ 33,810	\$ 14,948
Credit cards payable	26,876	5,259
Accrued expenses	1,083	—
Total accounts payable and accrued liabilities	<u>\$ 61,769</u>	<u>\$ 20,207</u>

#### NOTE 8 — RELATED PARTY TRANSACTIONS

On January 1, 2024, the Company entered into a rent-free, month-to-month lease arrangement with Dannel Stevens to occupy 1,500 square feet of office space in Naperville, Illinois. The property potentially rents for \$1,938 per month. Therefore, the Company incurred a lease expense and contributed capital of \$11,628 and \$11,628 during the year ended December 31, 2025, and 2024, respectively.

On January 7, 2025, the Company issued a Convertible Promissory Note to Stevens Financial Group, LLC (“SFG”), and Cleston Lord for an amount up to \$100,000. The note bears interest at 4.71%, matures in 90 days, and is convertible into shares of common stock at \$0.04 per share.

Effective February 21, 2025, the Company approved the Sixth Amendment to the Consulting Agreement between UMC, Inc. and Stevens & Associates Consulting, LLC, which extends the term to December 31, 2030

On March 31, 2025, SFG converted \$90,000 of principal and \$420 of interest into 2,260,513 common shares. As the amount converted exceeded the liability as of March 31, 2025, \$11,000 of Other Receivable-Related Party was disclosed on the balance sheet and has been offset by loans made to the Company from April 1<sup>st</sup> through April 29<sup>th</sup>.

On May 1, 2025, the Company issued a Convertible Promissory Note to Stevens Financial Group, LLC (“SFG”), and Cleston R. Lord, Jr., for an amount up to \$20,000. The note bears interest at 4.71%, matures in 60 days, and is convertible into shares of common stock at \$0.04 per share.

Effective May 15, 2025, the Company amended the existing note dated May 1, 2025, to a rolling convertible promissory note to which Stevens Financial Group, L.L.C. and Cleston R. Lord, Jr. will make available to the Company up to \$50,000 per calendar quarter to be used for general and working capital. At each quarter-end of calendar year 2025, any outstanding principal and accrued interest will be convertible into common stock of the Company at \$0.04 per share.

On June 30, 2025, SFG converted \$34,500 and \$111 of principal and interest under the May 1st Revolving Convertible Note, respectively, into 865,256 common shares.

On June 30, 2025, Mr. Lord converted \$7,500 and \$28 of principal and interest, respectively, into 188,196 common shares.

On June 30, 2025, Mr. Lord converted \$10,000 and \$183 of principal and interest, respectively, into 254,581 common shares.

On September 30, 2025, SFG converted \$63,274 and \$304 of principal and interest under the May 1st Revolving Convertible Note, respectively, into 1,589,459 common shares.

On September 30, 2025, Mr. Lord converted \$10,000 and \$79 of principal and interest, respectively, into 251,979 common shares.

On December 31, 2025, SFG converted \$76,783 and \$164 of principal and interest under the May 1st Revolving Convertible Note, respectively, into 1,923,681 common shares.

As of December 31, 2025, there were no amounts owed to SFG or Mr. Lord.



## **NOTE 9 – PREFERRED STOCK**

The Company has 250,000,000 preferred shares authorized at a par value of \$0.01 per share. As of December 31, 2025, and 2024, no preferred shares were issued and outstanding.

## **NOTE 10 — COMMON STOCK**

The Company has 750,000,000 common shares authorized at par value of \$0.01 per share. As of December 31, 2025, and 2024, there were 663,866,911 and 656,533,246 common shares issued and outstanding, respectively.

See Note 8 for issuance of shares to related parties.

## **NOTE 11 - JV INVESTMENT CAPITAL FUNDING**

On December 26, 2025, the Company entered into a JV investment agreement with a third-party investor (“JV investor”) and received funding of \$81,293 and contributed \$14,346, for the purchase of a collection portfolio. The total of \$95,638 was used to acquire the portfolio through its whole owned subsidiary SPV Parent. The SPV Parent transferred all rights of the asset to SPV. The agreement includes return milestones for principal, interest, and fees as applicable, yet payments are required only to the extent that there is sufficient collections of profits (Investment proceeds = Investment revenue – Investment expenses) from the portfolio purchased.

The general distribution of the profits is determined primarily by the return on each investors contribution at 13% per annum compounded annually, secondarily the repayment of the unreturned investment/principal contributed by each investor, thereafter, all profits from the investment is to be distributed 50:50 to each investor.

Given that the investment generates profits sufficient to repay capital and returns, 75% of JV Investor unreturned investment is to be paid by July 31, 2026 and the balance is to be repaid by February 28, 2027. If either due date is not met, the repayment obligation to the JV investor will become a senior obligation, requiring 100% of the JV investor’s unreturned investment and return to be paid in priority to the SPV’s unreturned investment and return. Thereafter, all profits will be split 50:50.

In the event SPV fails to remit profits as agreed within 10 Days from the applicable due dates July 31, 2026 and February 28, 2027, the JV investor shall have the right to charge the SPV fee of \$500 per day and is entitled to default interest at a rate of 3% per annum, which shall be added to the original interest determined at 13% per annum compounded annually from the date of such default.

If the portfolio’s performance is insufficient or ceases, repayment obligations correspondingly would be limited or potentially extinguished. Pursuant to these agreements, the SPV has granted a security interest in the underlying acquired portfolio, as collateral for any unreturned investment/principal and return (agreed interest and fees).

The SPV Parent provides a limited guarantee and broad indemnification for losses arising from fraud, willful misconduct, contractual breaches, or operational noncompliance, which represents a “bad acts” recourse provision rather than a general repayment guarantee.

## **NOTE 12 — COMMITMENTS AND CONTINGENCIES**

From time to time, the Company may be a defendant in pending or threatened legal proceedings arising in the normal course of its business. Management is not aware of any pending, threatened, or asserted claims.

On February 14, 2023, the Company entered into a Buyer Consultant Agreement (“Agreement”) between United MediCorp Acquisitions LLC and an unrelated party (“the Consultant 1”) whereby the Company was to receive consulting services and introductions to potential sellers of debt portfolios that it may be interested in purchasing. The Agreement has an initial one-year term that automatically renews for another year unless either party provides the other party written notice of termination, which would be effective only on the current term’s expiration. As compensation for the services performed, the Company will pay the Consultant a fee of 5% of the gross funded amount for all charged-off portfolios purchased and 2% of the gross funded amount for all performing portfolios purchased. As of December 31, 2025, one portfolio was acquired under this agreement. No portfolio was acquired under this agreement during the fiscal year ended December 31, 2024. During the years ended December 31, 2025, and 2024, the consultant fee expense was \$1,308 and \$0, respectively.

A Certificate of Authority to transact business is required in every state where the Company conducts business even it has no physical presence. The following are the certificates of authority issued to the company as of December 31, 2025 to transact business in various states:

**Certificates of Authority Issued:**

<b>Date of Issuance</b>	<b>State of Issuance</b>
March 15, 2024	Georgia
August 10, 2024	Alabama
August 10, 2024	Iowa
August 10, 2024	Kentucky
August 13, 2024	Delaware
August 13, 2024	Indiana
August 13, 2024	New Jersey
August 13, 2024	South Carolina
August 13, 2024	Vermont
August 16, 2024	Kansas
August 19, 2024	Florida
October 24, 2024	Ohio
October 29, 2024	Louisiana
December 1, 2024	New Hampshire
December 2, 2024	Rhode Island
December 8, 2024	West Virginia
December 16, 2024	District of Columbia
December 16, 2024	Mississippi
December 16, 2024	Tennessee
December 17, 2024	North Carolina
December 20, 2024	Pennsylvania
December 27, 2024	Connecticut
December 27, 2024	Maine
December 29, 2024	Missouri
December 30, 2024	Maryland
December 30, 2024	Oklahoma
July 3, 2025	Virginia
October 5, 2025	South Dakota
October 6, 2025	Montana
October 10, 2025	North Dakota
October 13, 2025	Arkansas
October 15, 2025	Colorado
October 25, 2025	New Mexico
October 26, 2025	Idaho
October 29, 2025	Nebraska
November 2, 2025	Minnesota
November 6, 2025	Wyoming
November 9, 2025	Wisconsin
November 9, 2025	Hawaii
November 10, 2025	Michigan
November 13, 2025	New York
November 14, 2025	Washington
November 15, 2025	California

On November 4, 2024, the Company hired Douglas L. Sawyer as President of United MediCorp Acquisitions LLC.

On November 4, 2024, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with an unrelated California-based collection agency (hereafter referred to as "the Agency 1") to obtain collection services. Under the terms of this agreement, the Agency is engaged to provide comprehensive debt collection services to UMCA, in exchange for a percentage of the gross amount collected from debtors. The Agency is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The Agreement is effective from November 4, 2024, and will remain in force unless terminated by either party by a thirty (30) day written notice. Upon termination, the Agency is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, the Agency is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. The Agency is to remit funds collected between every two weeks. The collection costs incurred under this agreement for the years ended December 31, 2025, and 2024 were \$7,982 and \$431, respectively.

On June 16, 2025, the Company entered into a consulting agreement with an unrelated third party (Consultant 2) to obtain strategic, operational, and compliance advisory services. Under the terms of the agreement, the consultant also serves in the capacity of acting operations officer. Fees are billed at a fixed hourly rate based on services performed. The Company recognizes such costs as incurred within operating expenses. The agreement does not require minimum service levels or fixed payments, and the agreement is for 12 months and can be terminated by a 30-day notice prior to the termination date.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with an unrelated New York-based collection agency (hereafter referred to as "Agency 2") to obtain collection services. Under the terms of this agreement, Agency 2 is engaged to provide comprehensive debt collection services to UMCA in exchange for a percentage of the gross amount collected from debtors. Agency 2 is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party by a thirty (30) day written notice. Upon termination, Agency 2 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency 2 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency 2 will deduct its fee and remit the remainder to UMCA by the close of business each Friday, including payments received through Tuesday of the same week. No collection costs were incurred under this agreement for the years ending December 31, 2025, and 2024.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with an unrelated Pennsylvania-based collection agency (hereafter referred to as "Agency 3") to provide third-party services. Under the terms of this agreement, Agency 3 is engaged to provide comprehensive debt collection services, in exchange for a percentage of the gross amount collected from debtors. Agency 3 is responsible for managing the entire collection process, including initial contact, negotiation, settlement, and, if necessary, coordination and management of legal proceedings. The Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party by a thirty (30) day written notice. Upon termination, Agency 3 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency 3 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency 3 will deduct its fee and remit the remainder to UMCA by the close of business each Friday, including payments received through Tuesday of the same week. Collection costs incurred under this agreement for the years ended December 31, 2025, and 2024, were \$2,721 and \$0, respectively.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with an unrelated Texas-based collection agency (hereafter referred to as "Agency 4") to provide third-party services. Under the terms of this agreement, Agency 4 is engaged to provide comprehensive debt collection services to UMCA in exchange for a percentage of the gross amount collected from debtors. Agency 4 is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party by a thirty (30) days' written notice. Upon termination, Agency 4 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency 4 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency4 will deduct its fee and remit the remainder to UMCA by close of business each Friday, including payments received through Tuesday of the same week. No collection costs were incurred under this agreement for the years ending December 31, 2025, and 2024.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with an unrelated Minnesota-based collection agency (hereafter referred to as "Agency 5") to provide third-party services. Under the terms of this agreement, Agency 5 is engaged to provide comprehensive debt collection services to UMCA in exchange for a percentage of the gross amount collected from debtors. Agency 5 is responsible for managing the entire collection process, including initial contact, negotiation, settlement, and, if necessary, coordination and management of legal proceedings. The Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party by a thirty (30) days' written notice. Upon termination, Agency 5 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency 5 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency 5 will deduct its fee and remit the remainder to UMCA by the close of business each Friday, including payments received through Tuesday of the same week. No collection costs were incurred under this agreement for the years ending December 31, 2025, and 2024.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with an unrelated New Jersey-based collection agency (hereafter referred to as "Agency 6") to provide third-party services. Under the terms of this agreement, Agency 6 is engaged to provide comprehensive debt collection services to UMCA in exchange for a percentage of the gross amount collected from debtors. Agency 6 is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party by a thirty (30) days' written notice. Upon termination, Agency 6 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency 6 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency 6 will deduct its fee and remit the remainder to UMCA by the close of business each Friday, including payments received through Tuesday of the same week. No collection costs were incurred under this agreement for the years ending December 31, 2025, and 2024.

In July 2025, the Company engaged an independent service auditor to perform a SOC 2 Type II examination of its systems related to security and confidentiality for the period August 1, 2024, through July 31, 2025. The engagement was completed in September 2025. The engagement was undertaken as part of the Company's ongoing compliance and risk management initiatives and is unrelated to the audit of the Company's financial statements.

On August 8, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Master Services Agreement with a cloud-based collection software service provider to be deployed across its receivables operations. The term of the agreement continues until all orders have either expired or have been terminated. The platform's advanced analytics and workflow automation are expected to increase recovery rates and reduce cycle times while offering robust audit trails and compliance tools that align with UMCA's regulatory obligations and internal governance standards.

On November 3, 2025, the Company, through its wholly-owned subsidiary, United MediCorp Acquisitions LLC, entered into a technology services agreement with an unrelated third-party provider to implement machine-learning-based models for account and portfolio segmentation and prioritization. The agreement supports the Company's strategic objective to enhance operational efficiency and data-driven decision-making across its receivables management functions. Management believes that integrating machine learning technology will improve portfolio performance, reduce operational costs, and enhance compliance oversight. The Company will continue to evaluate the effectiveness of this solution and its alignment with long-term strategic goals.

On December 17, 2025, the Company, through its wholly-owned subsidiary, United MediCorp Acquisitions LLC, entered into a Purchase and Sale Agreement to acquire a portfolio of charged-off healthcare receivable accounts (the "Investment 1") for \$93,763 from an unrelated party, funded through a combination of internal and external sources. The externally financed portion is recorded as a note payable on the Company's balance sheet as of December 31, 2025.

On December 29, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a collection services agreement with an unrelated third-party collections provider based in Utah, to support the recovery of certain delinquent accounts. The agreement authorizes the provider to perform collection activities in accordance with applicable federal and state requirements and includes a contingency-based fee structure, reporting obligations, and standard return-of-account provisions.

In connection with all collection provider agreements, the Company also executes a confidentiality agreement and a business associate agreement governing the exchange and protection of sensitive information, including any protected health information subject to HIPAA.

On December 30, 2025, the former President of the Company's wholly-owned subsidiary, United MediCorp Acquisitions LLC, separated from the organization. All final compensation was paid to him in accordance with Company policy and applicable agreements, and no amount was owed.

See Note 6 – Collection Receivables

See Note 8 – for details of Related Party Transactions.

### Note 13 — INCOME TAX

For the years ended December 31, 2025, and 2024, there was no provision for income taxes, and deferred tax assets were entirely offset by valuation allowances.

As of December 31, 2025, and 2024, the Company had net operating loss carryforwards of approximately \$10,126,524 and \$9,950,487, respectively. The carryforwards expire through the year 2044. The Company's net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.

The tax computations are as follows:

	<b>December 31, 2025</b>	<b>December 31, 2024</b>
Net losses before taxes	\$ (338,191)	\$ (176,037)
Adjustments to arrive at taxable loss:		
Permanent differences:	—	—
Temporary differences:	—	—
Taxable loss	\$ (338,191)	\$ (176,037)
Current Year Taxable loss	\$ (338,191)	\$ (176,037)
NOL carried forward prior year (tax return)	\$ (10,126,524)	\$ (9,950,487)
NOL carried forward at period end	\$ (10,463,120)	\$ (10,126,524)
Deferred Tax Asset - Federal Rate (21%)	\$ 2,197,590	\$ 2,126,570
Deferred Tax Asset - State Rate (8.7%)	\$ 910,430	\$ 881,008
Total Deferred Tax Asset	\$ 3,108,020	\$ 3,007,578
Valuation Allowance	\$ (3,108,020)	\$ (3,007,578)
Deferred tax per books	\$ —	\$ —

### NOTE 14 — SUBSEQUENT EVENTS

Management has evaluated subsequent events and transactions occurring through April 2, 2026, the date these audited consolidated financial statements were issued, and has determined that the following material subsequent events require disclosure.

On January 5, 2026, the Company entered into an Employment Agreement with Consultant 2 appointing her a Chief Operating Officer with an annual base salary of \$126,000 and eligibility for performance-based incentive compensation. The agreement provides for at-will employment under Illinois law and includes standard provisions relating to benefits, confidentiality, restrictive covenants, and termination. The Employment Agreement also terminates and supersedes the prior Consulting Services Agreement dated June 16, 2025, which is no longer in effect.

On January 30, 2026, the Company entered into a lease agreement with an unrelated lessor for approximately 4,048 square feet of office space in Miamisburg, Ohio, with an initial term of 62 months and an option to renew for two additional five-year periods on substantially the same terms. Base rent is structured with an initial rent abatement period, followed by monthly payments beginning at \$5,769 and subject to annual increases of 3%. The lease requires a security deposit of approximately \$5,769.

**Certificates of Authorities Issued Subsequent to December 31, 2025:**

<b>Date of Issuance</b>	<b>State of Issuance</b>
January 31, 2026	Alaska
February 3, 2026	Oregon
February 5, 2026	City of Chicago
February 23, 2026	Arizona
March 4, 2026	Massachusetts

On February 25, 2026, the Company, through its wholly-owned subsidiary, United MediCorp Acquisitions LLC, entered into a 36-month equipment and telecommunications services agreement with an unrelated AI-powered cloud communications platform provider to support the build-out of the Company's operations facility in Miamisburg, Ohio. The agreement includes a bundled arrangement for office telecommunications equipment and related services, subject to a multi-year service commitment, renewal provisions, and standard commercial terms, including early-termination fees and equipment-return requirements.

On March 1, 2026, the Company, through its wholly-owned subsidiary, United MediCorp Acquisitions LLC, entered into a consulting agreement with an unrelated independent advisory firm based in Chicago, Illinois. The agreement provides for strategic support for the development of the Company's debt acquisition and servicing operations, including market recognition and business development activities. The agreement includes a fixed monthly engagement fee of \$15,000 reimbursement of reasonable expenses, and a six-month initial term with an option for extension upon mutual agreement.

On March 2, 2026, the Company, through its wholly-owned subsidiary, United MediCorp Acquisitions LLC, executed a 36-month dedicated-internet and managed-network services agreement with an unrelated American multinational telecommunications provider to support connectivity and operational infrastructure at the Company's Ohio-based operations facility. The agreement includes monthly recurring service charges, non-recurring installation fees, minimum-payment obligations, and early-termination provisions applicable to long-term service commitments.

On March 16, 2026, the Company, through its wholly-owned subsidiary, United MediCorp Acquisitions LLC, entered into a services agreement with an unrelated offshore contact-center provider to support outbound collection operations. The agreement has an initial one-year term with automatic renewal provisions and establishes performance, staffing, and compliance requirements through defined Statements of Work. Services are provided on an hourly, per-agent basis, with monthly invoicing. The agreement includes standard provisions regarding regulatory compliance, data security, confidentiality, and audit rights. Management believes the engagement provides a cost-efficient means to expand collection capacity while maintaining appropriate oversight and compliance controls.

On March 27, 2026, the Company, through its wholly owned subsidiary, United MediCorp Acquisitions LLC, executed a nondisclosure agreement and related confidentiality provisions with a healthcare organization (an unrelated party) to evaluate, negotiate, and potentially consummate the purchase of certain medical accounts receivable. The agreement governs the exchange and protection of confidential information and restricts its use solely to the assessment of the contemplated transaction. The parties also agreed to enter into a Business Associate Agreement, as required, to ensure compliance with applicable privacy and security requirements in the event protected health information is exchanged.

The consolidated financial statements do not include any adjustments that may result from these conditions. Management is not aware of any other significant events that have occurred after the balance sheet date that would require adjustments to or disclosure in the consolidated financial statements.